TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04113915
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effect of treatment on immunity to obtain infection with hepatitis B\&C
Study: NCT04113915
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or parenteral steroid therapy for ITP
Study: NCT00765375
Drug: Bacteriostatic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: .1 cc bacteriostatic saline/lesion
Study: NCT05418426
Drug: Oral Reference
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: estradiol 1mg/progesterone 100 mg
Study: NCT04008069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously
Study: NCT00005775
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TrophAmine given any time that parenteral nutrition is required during the first 120 days of hospitalization.
Study: NCT00005995
Drug: shark cartilage extract AE-941
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02489487
Drug: VM-1500
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VM-1500 40 mg
Study: NCT00511199
Drug: NOMAC-E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomegestrol Acetate and Estradiol Tablets, 2.5 mg~NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
Study: NCT00456365
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)
Study: NCT00456365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily
Study: NCT03442972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03576820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive 0.9% sodium chloride solution via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
Study: NCT00679146
Drug: Thiocolchicoside+Ketoprofen
Normalized name: thiocolchicoside
DrugBank: Thiocolchicoside (DB11582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
Study: NCT01523574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given orally
Study: NCT00070083
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00070083
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02510248
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match AL-704
Study: NCT00855166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks
Study: NCT01272258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection
Study: NCT04160598
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
Study: NCT04160598
Drug: intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-15mg hyperbaric bupivacaine and 30µg fentanyl intrathecally injected
Study: NCT01767857
Drug: Xilonix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xilonix is a True Human Monoclonal Antibody targeting Interleukin 1 alpha, and is administered intravenously every 2 weeks with best supportive care until clinical or radiographic progression.
Study: NCT01767857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus best supportive care will be administered intravenously every 2 weeks until clinical or radiographic progression.
Study: NCT01825863
Drug: Saline 9%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01514578
Drug: TRV130A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 1 hour duration
Study: NCT04246749
Drug: [14C]-CRN00808
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug
Study: NCT04246749
Drug: CRN00808
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug
Study: NCT03173599
Drug: PNA 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The beginning dose is 40mg.
Study: NCT03173599
Drug: PNA 80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The single dose is 80mg.
Study: NCT03173599
Drug: PNA 160mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The single dose is 160mg.
Study: NCT03173599
Drug: PNA 240mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The single dose is 240mg.
Study: NCT03573089
Drug: Liberal phosphate target
Approvals — FDA: no, EMA: no, PMDA: no
Description: All phosphate-lowering medications in use at baseline will be discontinued. Phosphate-lowering medications will be prescribed only if serum phosphate concentration exceeds 2.50 mmol/L. The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
Study: NCT03573089
Drug: Intensive phosphate target
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be achieved by prescribing phosphate-lowering medications aimed to intensively lower serum phosphate concentration towards normal level (≤1.50 mmol/L). The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
Study: NCT04003142
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT03173599
Drug: PNA 360mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The single dose is 360mg.
Study: NCT03173599
Drug: PNA 480mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The single dose is 480mg.
Study: NCT03173599
Drug: PNA Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg.
Study: NCT00059267
Drug: HBIG, Epivir, Hepsera
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00141193
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03376529
Drug: SPR741
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg IV over 1 hour
Study: NCT00772525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: form: tablet~Route: oral
Study: NCT02308254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal administration
Study: NCT01635530
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline: 100mg tablet two times per day, four weeks
Study: NCT02489045
Drug: SHAPE measurement (Sonazoid ultrasoud contrast agent)
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
Study: NCT03324412
Drug: Treatment of MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg， 3 times a day, oral, for 24 weeks.
Study: NCT03324412
Drug: Treatment of MTX and TwHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate : 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）：20mg， 3 times a day, oral, for 24 weeks.
Study: NCT02465801
Drug: HSA-GCSF 1.2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human Serum Albumin GCSF 1.2mg at day 3 and Day 7
Study: NCT01603251
Drug: Artemether-lumefantrine combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-Lumefantrine (AL)combination; a placebo is given together with the first and fifth dose of AL
Study: NCT02465801
Drug: HSA-GCSF 1.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human Serum Albumin GCSF 1.5 mg at day 3 and Day 7
Study: NCT00966446
Drug: Unsupervised Decolonization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member.
Study: NCT00795756
Drug: Triple intrathecal therapy (TIT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy
Study: NCT00137423
Drug: SU011248 (sunitinib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg/day, oral, continuous daily dosing
Study: NCT01928329
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00330616
Drug: 323U66 SR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00697203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po daily for 12 weeks
Study: NCT00697203
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg po daily for 12 weeks
Study: NCT00966446
Drug: Supervised Decolonization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member. In addition, households are contacted by study stuff via phone or text messages to ensure compliance, to provide reminders to household members to perform the decolonization protocol as well as to answer any question/concerns household members may have.
Study: NCT03390686
Drug: HD204
Normalized name: Hydrocodone/Acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg IV every 3 weeks on Day 1
Study: NCT02621411
Drug: Substance use
Normalized name: reSET Substance Use Disorder Therapy Software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are found use of substances by preoperative screen
Study: NCT00114465
Drug: VSL#3
Normalized name: VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSL#3 1 sachet twice a day
Study: NCT00385515
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days
Study: NCT05283057
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of placebo that is similar to Empagliflozin in physical appearance
Study: NCT02735629
Drug: CX1739 - 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampakine CX1739 - 300 mg
Study: NCT02735629
Drug: CX1739 - 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX1739 - 600 mg
Study: NCT02735629
Drug: CX1739 - 900 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX1739 - 900 mg
Study: NCT02735629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to 300 mg CX1739
Study: NCT00003492
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT04993989
Drug: Iberogast (STW5, BAY98-7411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survey without any intervention assigned in the study.
Study: NCT01673451
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
Study: NCT03350633
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine will be orally given at a dose of 2-3 mg/kg/d
Study: NCT01333059
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01333059
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05451147
Drug: Chhinnavahni Kashaya Vati along with Agnimantha Kwatha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Chhinnavahni Kashaya Vati Form : Tablet Dose: 1g TDS (2x500 mg), Before meals Mode of Administration: Oral Anupaan: 20 ml of Agnimantha Kwatha Duration: 3 Months
Study: NCT02733367
Drug: Infacort®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infacort® is a dry granule formulation of hydrocortisone stored in capsules available in different strengths (0.5, 1.0, 2.0 and 5.0 mg).
Study: NCT01683955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mL 0.9% sterile saline
Study: NCT03150888
Drug: Antihypertensive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.
Study: NCT01133301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During 3 weeks of the study, Placebo will be administrated (daily)
Study: NCT01490476
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg per os / day or 05mg per os / day with 12 month
Study: NCT01019642
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: no active principles given.
Study: NCT00004323
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004323
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01019174
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
Study: NCT01500135
Drug: TachoSil®
Approvals — FDA: no, EMA: no, PMDA: no
Description: TachoSil® is a sterile, ready-to-use, absorbable patch for intra-operative topical application. It consists of an equine collagen patch coated with fibrin glue components: human fibrinogen and human thrombin.
Study: NCT01500135
Drug: Surgicel® Original
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgicel® Original is an absorbable hemostat (oxidized regenerated cellulose)
Study: NCT00595075
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo identical in appearance to active experimental drug x 1 dose
Study: NCT02167685
Drug: CMX001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02800746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline 100 ml is intravenously administered on 7-10 day before surgery
Study: NCT01545310
Drug: SLV354
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of ABT-354
Study: NCT00154245
Drug: Enteric-Coated Mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03715829
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03715829
Drug: PF06700841
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet taken QD
Study: NCT00375739
Drug: PEP005
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00020176
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00721110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo boluses and infusions will be substituted
Study: NCT00984750
Drug: acetyl-L-carnitine/statin (simvastatin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetyl-L-carnitine: 4 tablets of 500 mg a day~simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
Study: NCT00984750
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo: 4 tablets of 500 mg a day simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
Study: NCT01681849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
Study: NCT02529956
Drug: UCB4940
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Active Substance: UCB4940~* Pharmaceutical Form: Solution for infusion~* Concentration: 80 mg/ml~* Route of Administration: Intravenous use
Study: NCT01950039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally in divided doses over 3 months
Study: NCT04074837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo liquid suspension
Study: NCT03338920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose monohydrate powder administered via nosepiece
Study: NCT01514422
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 100 to 300mg per day for 8 weeks
Study: NCT04203771
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen syrup at 20-30 mg/Kg of body weight, orally every 8 hours (t.i.d), for 7 days
Study: NCT00003680
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003680
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003680
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003680
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01813357
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: encapsulated tablet 20mg daily
Study: NCT01271231
Drug: Scaling and root planing plus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single session of scaling and root planing using ultrasonic device. placebo tablets 500 mg, 1 tablet every 24 hours for 3 days
Study: NCT01271231
Drug: Scaling and root planing plus azythromycin
Normalized name: rauwolfia alkaloids, whole root and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single session of scaling and root planing using ultrasonic device. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
Study: NCT01271231
Drug: Prophylaxis plus azythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental polishing using prophylaxis paste and rubber cups. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
Study: NCT00713154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel in 100 ml tube, two 100 ml tubes prior to each radiation treatment
Study: NCT02231580
Drug: BN82451B
Approvals — FDA: no, EMA: no, PMDA: no
Description: BN82451B capsule
Study: NCT02231580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT02603497
Drug: ASP015K
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03673072
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Can be selected by Investigator's Choice
Study: NCT02353598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window.
Study: NCT03121547
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium tablet
Study: NCT00604331
Drug: Pyruvate
Normalized name: Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium pyruvate 300 mmol/L, 360 mL/h i.c. over 30 minutes.
Study: NCT00149084
Drug: Lansoprazole, clarithromycin, amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01270711
Drug: Study Drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: non interventional study - usage as per usual care
Study: NCT02298946
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/m(2) IV on day 0.
Study: NCT00140920
Drug: MK0966; rofecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00140920
Drug: Comparator: diclofenac 2x 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03717454
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The medication will continue if DA causes tumors to shrink.
Study: NCT03555994
Drug: MEDI0382
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI0382 administered subcutaneously
Study: NCT03555994
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously
Study: NCT03110510
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5FU 400mg/m2 bolus and then 2400mg/m2, continuous infusion D1-2
Study: NCT03110510
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 200 mg/m2